Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-5780 and PD-1 Inhibitor in Advanced Solid Tumors
NCT06398418Phase 1Recruiting
- Sponsor
- Rise Therapeutics
- Start
- Aug 2025
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R-5780 in solid tumor, melanoma, basal cell carcinoma (BCC) and 1 more, sponsored by Rise Therapeutics. Primary endpoint: Adverse Events at 4 weeks. Started Aug 2025; status: recruiting.
02
Drugs
R-5780
03
Conditions
solid tumormelanomabasal cell carcinoma (BCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT06398418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398418.